{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:49:57Z","timestamp":1761518997193},"reference-count":59,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,1]]},"abstract":"<jats:p>The approach to a patient with acromegaly and persistent disease after surgery requires a complex diagnostic assessment. Acromegaly is a chronic and insidious disease that is associated with multisystem comorbidities, including cardiovascular disease, hypertension, sleep apnea syndrome, colon polyposis, arthropathy, and metabolic complications including glucose intolerance and type 2 diabetes mellitus. Patients also have a variety of signs and symptoms, including headache, arthralgias, carpal tunnel syndrome, sweating, fatigue, and psychological issues that impact significantly on quality of life. The recommended approach to the evaluation of the postoperative patient includes a biochemical assessment, with measurement of serum IGF-I along with a glucose-suppressed GH value, radiological assessment to determine location of residual tumor and presence of mass effects, a physical examination for evidence of skeletal and soft tissue overgrowth and related signs of acromegaly, and a thorough clinical assessment for the presence of comorbidities. Repeat surgery is indicated if there is residual tumor that is surgically accessible and there may be a chance for surgical cure, or if there are persistent mass effects upon the optic chiasm. Otherwise, medical therapy is indicated, utilizing somatostatin analogs, dopamine agonists, and pegvisomant, a GH receptor antagonist. Radiation therapy is usually relegated to situations where medical therapy is ineffective or poorly tolerated or where patients would prefer not to sustain the cost of long-term medical therapy. The choice of therapy requires close dialog among endocrinologists, neurosurgeons, radiation therapists, and neuroophthalmologists for optimal care of patients.<\/jats:p>","DOI":"10.1210\/jc.2010-0670","type":"journal-article","created":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T22:46:35Z","timestamp":1283899595000},"page":"4114-4123","source":"Crossref","is-referenced-by-count":28,"title":["Approach to the Patient with Persistent Acromegaly after Pituitary Surgery"],"prefix":"10.1210","volume":"95","author":[{"given":"Laurence","family":"Katznelson","sequence":"first","affiliation":[{"name":"Departments of Medicine and Neurosurgery, Stanford University School of Medicine, Stanford, California 94305"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071616060595000_R1","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2265.2007.02836.x","article-title":"Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.","volume":"67","author":"Pokrajac","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R4","first-page":"293","article-title":"An audit of outcome of treatment in acromegaly.","volume":"86","author":"Bates","year":"1993","journal-title":"Q J Med"},{"key":"2020071616060595000_R5","first-page":"526","article-title":"Criteria for cure of acromegaly: a consensus statement.","volume":"85","author":"Giustina","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R6","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1210\/jc.2004-1381","article-title":"A nationwide survey of mortality in acromegaly.","volume":"90","author":"Kauppinen-Ma\u0308kelin","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R7","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1210\/jc.2003-031584","article-title":"Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.","volume":"89","author":"Ayuk","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R8","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly.","volume":"95","author":"Giustina","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1210\/jc.2003-031316","article-title":"Significance of \u201cabnormal\u201d nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.","volume":"89","author":"Freda","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R10","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1210\/jcem.87.8.8658","article-title":"Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.","volume":"87","author":"Dimaraki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","article-title":"Acromegaly.","volume":"26","author":"Nabarro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1022145116901","article-title":"Self image and quality of life in acromegaly.","volume":"5","author":"Pantanetti","year":"2002","journal-title":"Pituitary"},{"key":"2020071616060595000_R13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1010-5182(05)80274-4","article-title":"Typical changes in the viscerocranium in acromegaly.","volume":"19","author":"Ku\u0308nzler","year":"1991","journal-title":"J Craniomaxillofac Surg"},{"key":"2020071616060595000_R14","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1210\/jc.2004-2297","article-title":"Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life.","volume":"90","author":"Biermasz","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R15","first-page":"24","article-title":"The acromegalic arthropathy.","volume":"28","author":"Colao","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"2020071616060595000_R16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2009-1912","article-title":"Endocrine aspects of obstructive sleep apnea.","volume":"95","author":"Attal","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1563-2571.2000.00106.x","article-title":"Prevalence of diabetes in acromegaly and Cushing syndrome.","volume":"27","author":"Biering","year":"2000","journal-title":"Acta Medica Austriaca"},{"key":"2020071616060595000_R18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","article-title":"Impaired \u03b2-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.","volume":"52","author":"Kasayama","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).","volume":"151","author":"Mestron","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000095530","article-title":"Acromegaly and the cardiovascular system.","volume":"83","author":"Lombardi","year":"2006","journal-title":"Neuroendocrinology"},{"key":"2020071616060595000_R21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11154-007-9063-z","article-title":"Acromegaly: re-thinking the cancer risk.","volume":"9","author":"Loeper","year":"2008","journal-title":"Rev Endocr Metab Disord"},{"key":"2020071616060595000_R22","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly.","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"2020071616060595000_R23","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.","volume":"83","author":"Orme","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R24","first-page":"3223","article-title":"The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients.","volume":"80","author":"Delhougne","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R25","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1210\/jcem.85.9.6775","article-title":"The prevalence and characteristics of colorectal neoplasia in acromegaly.","volume":"85","author":"Renehan","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/jc.2004-0240","article-title":"Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy.","volume":"90","author":"Terzolo","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2008-1371","article-title":"The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.","volume":"94","author":"Carmichael","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-08-0822","article-title":"Pituitary-independent effect of octreotide on IGF1 generation.","volume":"160","author":"Pokrajac","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R29","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R30","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R31","first-page":"2356","article-title":"Prediction of efficacy of octreotide therapy in patients with acromegaly.","volume":"81","author":"Colao","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R32","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1210\/jc.2004-2466","article-title":"A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.","volume":"90","author":"Melmed","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.01824","article-title":"Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.","volume":"152","author":"Petrossians","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R34","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update.","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients.","volume":"83","author":"Abs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.2004.02082.x","article-title":"Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.","volume":"61","author":"Cozzi","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R37","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1530\/EJE-08-0306","article-title":"Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.","volume":"159","author":"Moyes","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease.","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071616060595000_R39","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"2020071616060595000_R40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.","volume":"358","author":"Lely","year":"2001","journal-title":"Lancet"},{"key":"2020071616060595000_R41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2265.2008.03469.x","article-title":"Long-term experience of pegvisomant therapy as a treatment for acromegaly.","volume":"71","author":"Higham","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-08-0843","article-title":"Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.","volume":"160","author":"Neggers","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R44","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03345774","article-title":"Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy.","volume":"32","author":"Ghigo","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"2020071616060595000_R45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2009-1239","article-title":"Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study.","volume":"95","author":"Buhk","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","article-title":"Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.","volume":"156","author":"Schreiber","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R47","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2008-0833","article-title":"Lipodystrophy in patients with acromegaly receiving pegvisomant.","volume":"93","author":"Bonert","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1365-2265.2003.01704.x","article-title":"Radiotherapy in acromegaly: the argument against.","volume":"58","author":"Barkan","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R49","first-page":"2068","article-title":"Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure.","volume":"85","author":"Powell","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R50","first-page":"1269","article-title":"Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery","author":"Jagannathan","year":"2008","journal-title":"Neurosurgery 62:1262\u20131269; discussion"},{"key":"2020071616060595000_R51","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2265.2006.02513.x","article-title":"Gamma knife radiosurgery for acromegaly\u2014long-term experience.","volume":"64","author":"Jezkova\u0301","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616060595000_R52","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1365-2265.2009.03589.x","article-title":"Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study.","volume":"71","author":"Ronchi","year":"2009","journal-title":"Clin Endocrinol"},{"key":"2020071616060595000_R53","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1210\/jcem.85.3.6464","article-title":"Octreotide may act as a radioprotective agent in acromegaly.","volume":"85","author":"Landolt","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R54","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2005-0311","article-title":"Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion.","volume":"90","author":"Castinetti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/eje.0.1510309","article-title":"Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly.","volume":"151","author":"Herrmann","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071616060595000_R56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.14219\/jada.archive.1987.0127","article-title":"Acromegaly and resulting myofascial pain and temporomandibular joint dysfunction: review of the literature and report of case.","volume":"114","author":"Hampton","year":"1987","journal-title":"J Am Dent Assoc"},{"key":"2020071616060595000_R57","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1210\/jc.2007-2084","article-title":"Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.","volume":"93","author":"Arafat","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R58","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1210\/jc.2008-0235","article-title":"Should we still use glucose-suppressed growth hormone levels for the evaluation of acromegaly?","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616060595000_R59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1472-6823-9-20","article-title":"Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation.","volume":"9","author":"Moore","year":"2009","journal-title":"BMC Endocr Disord"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/9\/4114\/10412500\/jcem4114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/9\/4114\/10412500\/jcem4114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:05:25Z","timestamp":1594955125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/95\/9\/4114\/2835200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2010-0670","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}